Michael Makris/LinkedIn
Dec 18, 2025, 23:25
Michael Makris: Excellent Article in This Week’s NEJM Explains Word Estimand Clearly
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
“Do you know what is an “estimand”?
I had never heard of the word until today, but this excellent article in this week’s New England Journal of Medicine (NEJM) explains it clearly.
Essentially, it is the effect of actually taking a drug in a randomised trial. Although simplistically attractive there are good reasons why Intention to Treat (ITT) analysis should remain the gold standard. I can see estimands being used increasingly by manufacturers and sponsored speakers at meetings.”
Discover the latest in Hemostasis Today.
-
Feb 26, 2026, 15:58Daniel Victor Ortigoza։ Lipoprotein(a) Levels Predict Long-Term Cardiovascular Risk in Women
-
Feb 26, 2026, 15:51Augustina Isioma Ikusemoro: The Real Miracle in Trauma Care Happens Behind the Scenes
-
Feb 26, 2026, 15:42Jim Hoffman։ Targeting NETosis to Improve Perfusion and Reduce Thrombosis in AMI
-
Feb 26, 2026, 15:40Elvira Grandone: ISTH Launches An International Survey to Capture Real-World Practice of Pregnancy Anemia
-
Feb 26, 2026, 15:39Ashok Yadav: Placental Glycogen as a Vital Energy Reserve for Fetal and Placental Health
-
Feb 26, 2026, 15:37Nayab Ahmed: Main Reasons for Washing Platelet-Rich Plasma
-
Feb 26, 2026, 15:36Robert Negrin Shares His Outlook for the Year Ahead as ASH President
-
Feb 26, 2026, 15:24Nancy Shapiro: Excited to See This Publication on Current Landscape of Anticoagulation Stewardship Released
-
Feb 26, 2026, 15:15Ahmed Nasreldein: Stay Current on Key Updates in Ischemic and Hemorrhagic Stroke